KIT
"sugarBEAT is soon
expected to be available
on-line for purchase
directly by consumers on
a subscription basis, selffunded by people with
diabetes who want to be
able to access their blood
glucose data in an easy,
pain-free way.
- Nemaura Medical SVP
Fred Schaebsdau
ABOVE: A sugarBEAT
device. RIGHT: sugarBEAT
sensor with transmitter
worn on the arm with
glucose data seen via an
app on a smartphone.
Nemaura Medical is also providing a digital
offering to users. The company have
stated that this is designed as "a holistic
solution under the brand BEATdiabetes,
for the prevention and management
of diabetes through partnering and
developing services including apps
to track and provide personal lifestyle
recommendations to patients according
to their glucose levels. Alarms can be
set that will show in the app, or a text
message can be sent to the user's mobile
phone that predicts a high or a low based
on the rate of change of the glucose
readings going up or down. There will be
1:1 coaching and routine measurement
of other parameters, such as steps
and sleep, that allow improved disease
management through monitoring. With
our link up with the Changing Health app,
and it is expected that people will even be
given personalised nutritional information.
The company hopes to expand that
offering further in the future."
The sugarBEAT sensors will be
calibrated with at least one finger-stick
calibration being needed daily wear.
While initially aimed at adult T2s, later
trials will look at children gestational
use. T1's can also use the device as an
adjunct to fingerstick testing, and the
non-consecutive days use means the
large majority of T1's that do not use
CGMs can now check their daily glucose
profiles as and when they desire. In terms
of accuracy, the criteria used for sensors
is the MARD standard (Mean absolute
relative difference) and more recent
MARD reliability index (MRI). sugarBEAT's
MARD rating is 12.3, with a single finger
prick calibration and 11.9 with two finger
stick calibrations. Libre launched when its
MARD rating was 13.3.
Watch this space
This is going to be interesting, and we'll
report on it further as things progress. It's
about time Type 2s got a look in.